Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
POLYGYNAX® is a broad spectrum combination of nystatin, neomycin and polymixin B indicated
for the local treatment of vaginitis due to sensitive germs and treatment of non specific
vaginitis of adults. POLYGYNAX® has been marketed in France since 1969.
Nevertheless, despite the well established use of POLYGYNAX®, there is no clinical study
supporting the interest of the combination of antifungal and antibiotics agents versus
antifungal agent alone.
The aim of this project is to demonstrate that POLYGYNAX® is more effective than miconazole
in the treatment of women experiencing symptoms of infectious vaginitis.
Phase:
Phase 3
Details
Lead Sponsor:
Laboratoire Innotech International
Collaborators:
International Clinical Trials Association Venn Life Sciences